Terézia Pázmanová, Veronika Pokorná, Iveta Hartmannová, Lenka Tarabčáková
An increasing number of women with cardiovascular (CV) diseases during pregnancy and lactation causes the rise in the
CV drugs usage. The decision regarding pharmacological treatment has to take into consideration the specifics of given
conditions, benefits for the mother, as well as potential risks for the foetus/infant. Such decision must examine the
differences in foetal pharmacokinetics and the factors affecting the transfer of the drug into breast milk – lipophilicity,
low molecular weight, low protein binding. There is no clear recommendation regarding drug usage during pregnancy
and lactation. Treatment of CV diseases should not be the contraindication of lactation. In emergency, the drugs that
are not mentioned in the recommendation should not be denied to the women in need.